[Hinews] SEOUL, South Korea — Caregen, a South Korean biotech company specializing in peptide therapeutics, announced on July 30 that its weight-loss peptide, Korglutide, has been officially registered as a health supplement with Indian health authorities.

This regulatory milestone clears the way for Caregen to distribute and commercialize Korglutide in India, one of the world’s fastest-growing markets for health and wellness products. Korglutide, an oral glucagon-like peptide-1 (GLP-1) receptor agonist, offers a competitive edge over injectable GLP-1 therapies due to its ease of use and ability to minimize muscle loss during weight reduction.

In a 12-week clinical trial conducted in India, Korglutide demonstrated significant efficacy, with participants achieving an average body weight reduction of 10.8%. The trial also showed that weight loss was primarily driven by reductions in body fat, with no reported cases of treatment discontinuation, underscoring the drug’s safety and tolerability.

Mechanism of action for Korglutide, illustrating its role in weight management (Provided by Caregen).
Mechanism of action for Korglutide, illustrating its role in weight management (Provided by Caregen).


As concerns grow over side effects associated with injectable GLP-1 therapies, Korglutide is positioned as a promising oral alternative. Caregen plans to launch the peptide in multiple formulations, including powders and films, and is partnering with major Indian pharmaceutical companies to expand its distribution network.
“Korglutide represents a next-generation weight management solution, combining cutting-edge peptide technology with a strong safety profile,” said Yongji Chung, CEO of Caregen. “We are confident it will quickly establish a foothold in India’s premium health market.”

키워드

#케어젠#체중감량#펩타이드#코글루타이드
저작권자 © Hinews 무단전재 및 재배포 금지
ad